Partner David Rosen was quoted in a Memphis Business Journal article, “A COVID-19 vaccine this year? It’s a long shot, but it’s possible,” about drug companies considering the use of a little-known regulatory tool to push their COVID-19 vaccines into Americans’ hands before the end of the year.
Rosen, who chairs the firm’s FDA regulatory practice, said the government’s decision to enact the Public Readiness and Emergency Preparedness (PREP) Act in response to the COVID-19 outbreak limits the legal repercussions that drugmakers could face if their COVID-19 products cause physical injury, death and other ill effects to users.
(Subscription required.)
People
Related News
17 April 2024
In the News
Steven Barth on Allure of Take-Private Deals – 'Public markets aren’t what they’re cracked up to be'
Foley & Lardner LLP partner Steven Barth offers extensive insight on the growing trend of family-owned consumer and retail businesses aiming to go private in the Axios article, “Family-owned companies see allure in take-private deals.”
16 April 2024
In the News
Claire Marblestone Assesses Increased Scrutiny of CA Health Care Transactions
Foley & Lardner LLP partner Claire Marblestone is quoted in the Law360 article, “Struggling Hospitals Seek Mergers As Regulators Push Back.”
15 April 2024
In the News
Nathaniel Lacktman Joins Double Take by Newton Podcast to Talk Telemedicine
Foley & Lardner LLP Nathaniel Lacktman appeared on Newton Investment Management’s Double Take by Newton podcast episode “Modernizing Medicine” to discuss the health care industry’s digital evolution and the benefits of telemedicine.